Product Description
5-Amino-1mq (5-amino-1-methylquinoline-1-iodide) is a selective small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.2 μM. It specifically binds to residues within the NNMT substrate binding site, blocking the methylation metabolic pathway of nicotinamide, thereby regulating intracellular NAD+ levels and energy metabolism homeostasis. This compound has shown unique value in metabolic regulation, mitochondrial function maintenance, and cell differentiation research, and has attracted particular attention in the fields of skeletal muscle stem cell activation and muscle regeneration.
Product Advantages
The core value of 5-amino-1mq lies in its metabolic regulatory potential as an NNMT inhibitor. NNMT is highly expressed in adipose tissue and liver and is considered a key regulatory node in obesity, metabolic syndrome, and age-related metabolic decline. By inhibiting NNMT activity, it can serve as an important molecular tool for the following research directions:
Metabolic and Obesity Research: Overexpression of NNMT in white adipose tissue depletes NAD+ and inhibits energy expenditure. Researchers are exploring whether it can reduce the accumulation of white adipose tissue by inhibiting NNMT, while maintaining muscle mass and improving glucose homeostasis and insulin sensitivity.
Muscle Regeneration and Aging: In vitro studies have shown that it promotes myoblast differentiation; in aged mouse models, it enhances the fusion and regenerative capacity of muscle stem cells. In post-injury muscle repair experiments, the treatment group showed a higher incidence of proliferating muscle stem cells and more fused muscle nuclei, indicating its research potential in combating age-related muscle decline.
Mitochondrial Function and NAD+ Metabolism: NNMT affects cellular energy metabolism by consuming methyl donors and NAD+. 5-amino-1mq, by blocking this pathway, may indirectly increase NAD+ availability, providing a new entry point for studying mitochondrial bioenergetics and longevity-related signaling pathways.